Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327612 · ClinicalTrials.gov registry record · Phase 2
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01327612 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 12 participants.
The verdict
NCT01327612, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease progression whose previous studies were closed.
Interventions
- BIOLOGICAL Ganitumab
- BIOLOGICAL Bevacizumab
- DRUG Modified FOLFOX6
- BIOLOGICAL Conatumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-03-03 |
| Est. Completion | 2020-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01327612
The ClinicalTrials.gov registry entry for NCT01327612 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ganitumab is the first listed.
NCT01327612 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01327612 about?
NCT01327612 is a clinical study titled "Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)". The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease progression whose previous studies were closed.
What is the current status of trial NCT01327612?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2011-03-03. Estimated completion is 2020-02-05.
What interventions are being tested in trial NCT01327612?
The interventions under investigation include: Ganitumab (BIOLOGICAL), Bevacizumab (BIOLOGICAL), Modified FOLFOX6 (DRUG), Conatumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01327612?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.